Stéphanie van Hoppe (Stephanie van Hoppe)

Publication Activity (10 Years)

Years Active: 2017-2020
Publications (10 Years): 4

Top Topics

Multidrug Resistant

Cancer Stem Cells

Chronic Lymphocytic Leukemia

Top Venues

Molecular pharmaceutics

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Johannes J M Rood, Amer Jamalpoor, Stéphanie van Hoppe, Matthijs J van Haren, Roeland E Wasmann, Manoe J Janssen, Alfred H Schinkel, Rosalinde Masereeuw, Jos H Beijnen, Rolf W Sparidans
Extrahepatic metabolism of ibrutinib. Investigational new drugs 39 (1) (2020)
Alejandra Martínez-Chávez, Stéphanie van Hoppe, Hilde Rosing, Maria C Lebre, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability. Molecular pharmaceutics 16 (9) (2019)
Stéphanie van Hoppe, Johannes J M Rood, Levi Buil, Els Wagenaar, Rolf W Sparidans, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Molecular pharmaceutics 15 (11) (2018)
Anita Kort, Stéphanie van Hoppe, Rolf W Sparidans, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel
Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). Molecular pharmaceutics 14 (10) (2017)